Clinical Trial Update: Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease [Phase 3]

View source ↗

Summary

Phase 3 study TA-650 in Kawasaki disease refractory to initial IVIG therapy has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kawasaki Disease

Drugs mentioned

• TA-650

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin | Phase 3 | Status: COMPLETED | Results posted: 2018-09-26